Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Read in Swedish

Vitrolife AB (publ): Conference call interim report

13:00 / 6 April 2023 Vitrolife Press release

Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1, 2023. The presentation will be held in English.

Time: Friday 21 April, 2023 at 10.00 a.m. CET.

To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference.

Vitrolife Group participants:
Jón Sigurdsson, Interim CEO
Patrik Tolf, CFO
The press release for the interim report will be released at 8.00 CET on the same day.
Before the conference call, presentation material will be available at the company web page.

A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 0315396#.

Gothenburg, 6 April 2023


Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group's products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.

Show as PDF

Show original from Cision


This information was distributed by Cision